Dr. Rivera on Screening in Lung Cancer

M. Patricia Rivera, MD
Published: Thursday, Apr 05, 2018



M. Patricia Rivera, MD, professor of medicine, UNC Chapel Hill, UNC Lineberger Comprehensive Cancer Center, discusses the recent adoption of lung cancer screening into clinical practice.

Screening came about following the publication of The National Lung Screening Trial. The randomized trial compared CT scan with chest X-ray in smokers over the age of 55 with a 30-year smoking history. The trial demonstrated the first reduction in mortality for patients who had been screened with CT scan.

In 2014, the United States Preventative Task Force gave this a B recommendation. In 2015, Medicare approved screening, and since then it has become more available. However, it is considerably underutilized, says Rivera. As of 2015, only 3.9% of eligible patients were being screened in the United States. This may be due, in part, to the difficulty of getting an accurate smoking history.
 


M. Patricia Rivera, MD, professor of medicine, UNC Chapel Hill, UNC Lineberger Comprehensive Cancer Center, discusses the recent adoption of lung cancer screening into clinical practice.

Screening came about following the publication of The National Lung Screening Trial. The randomized trial compared CT scan with chest X-ray in smokers over the age of 55 with a 30-year smoking history. The trial demonstrated the first reduction in mortality for patients who had been screened with CT scan.

In 2014, the United States Preventative Task Force gave this a B recommendation. In 2015, Medicare approved screening, and since then it has become more available. However, it is considerably underutilized, says Rivera. As of 2015, only 3.9% of eligible patients were being screened in the United States. This may be due, in part, to the difficulty of getting an accurate smoking history.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x